Product
SLN360
2 clinical trials
6 indications
Indication
Cardiovascular DiseasesIndication
AtherosclerosisIndication
Lipoprotein(a)Indication
HyperlipidemiaIndication
DyslipidemiaIndication
Elevated Lp(a)Clinical trial
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsStatus: Active (not recruiting), Estimated PCD: 2024-01-11
Clinical trial
A Randomised, Double-blind, Placebo Controlled, First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN360 in Subjects With Elevated Lipoprotein(a)Status: Completed, Estimated PCD: 2023-08-23